Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + vinorelbine + ifosfamide + filgrastim (Insel Gruppe)
- Development stage
- Unknown
- Lead developer
- Insel Gruppe
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
Gemcitabine + vinorelbine + ifosfamide + filgrastim (also known as the F-GIV or FGIV regimen) is a multi-agent chemotherapy combination used as salvage therapy for relapsed or refractory lymphoma, including both Hodgkin lymphoma and non-Hodgkin lymphoma. Developed as a risk-adapted outpatient approach, the regimen combines the cytotoxic effects of gemcitabine (a nucleoside analog antimetabolite), vinorelbine (a vinca alkaloid microtubule inhibitor), and ifosfamide (a DNA-alkylating agent). Filgrastim, a recombinant granulocyte colony-stimulating factor (G-CSF), is included to provide hematopoietic support and reduce the incidence of neutropenia, allowing for intensive treatment in an ambulatory setting. The regimen was evaluated in a Phase II trial sponsored by Bayside Health in Australia for patients who failed prior therapies or stem cell transplants.
- Other names
- gemcitabine + vinorelbine + ifosfamide + filgastrimFGIV regimenF-GIV regimengemcitabine, vinorelbine, ifosfamide, and filgrastim
02
Targets
CSF3R (Granulocyte colony-stimulating factor receptor)DNA polymerase familyRNR (Ribonucleotide reductase)TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on gemcitabine + vinorelbine + ifosfamide + filgrastim (Insel Gruppe).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + vinorelbine + ifosfamide + filgrastim (Insel Gruppe).